You are cordially invited to a royalty free TDF(TAF)/FTC COMPULSORY LICENSE PARTY

When: NOW!
Where: USA!

RSVP to #PrEPparty
Oral tenofovir (TDF) in combination with emtricitabine (FTC) known as PrEP is the only prevention technology that does not require partner knowledge or co-operation. When taken as directed, PrEP is highly effective at preventing someone from acquiring HIV.

But it ain’t no party for people in the USA who are at risk of getting HIV but can’t afford to access PrEP. Only about 167,000 people in the USA are currently taking it, just 10% of those it is estimated could benefit because it is unaffordable.

Gilead has set the price of PrEP at about $2,000 per month in the USA, while generic versions available in other countries are sold for as little as $6 per month. Gilead made $3 billion in sales from the drug in 2018; however, the company spent almost nothing to research PrEP and bring it to market. Taxpayers funded most of the clinical research that was needed to prove effectiveness. A newer version of PrEP is about to be launched with a new version of tenofovir (TAF) with a much longer period of monopoly protection—how much will they set the price for this?

We cannot afford not to make this prevention option available to all. It is time for the US government to join the party and issue a COMPULSORY LICENSE to ensure access to multiple sources of more affordable generic PrEP NOW!